Clinical Trials

624 enrolled 17 charts

Breast Neoplasms

NCT01602380 2026-02-27

FALCON

462 enrolled 20 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT02763566 2026-02-05

MONARCH plus

463 enrolled 20 charts

Breast Neoplasms

NCT05169567 2026-01-16

postMONARCH

368 enrolled 14 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02107703 2025-10-21

MONARCH 2

669 enrolled 22 charts 1 FDA

Breast Neoplasms

NCT03778931 2025-09-15

EMERALD

478 enrolled 16 charts 1 FDA

Breast Neoplasms

NCT04975308 2025-07-11

EMBER-3

874 enrolled 29 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT00253422 2025-06-04

SoFEA

698 enrolled 19 charts

Breast Neoplasms

NCT02437318 2025-02-13

SOLAR-1

572 enrolled 22 charts 1 FDA

BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT02028507 2024-09-25

PEARL

693 enrolled 40 charts

Breast Neoplasms

NCT02422615 2023-11-30

MONALEESA-3

726 enrolled 17 charts 1 FDA

BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

NCT00545077 2023-03-31

Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women

380 enrolled 21 charts

Breast Neoplasms

NCT02340221 2022-07-12

SANDPIPER

Phase 3 Terminated

631 enrolled 49 charts

Breast Neoplasms

NCT01610284 2020-08-25

BELLE-2

1,147 enrolled 20 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00390455 2019-12-20

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

295 enrolled 18 charts

Breast Neoplasms

NCT01633060 2019-01-30

BELLE-3

Phase 3 Terminated

432 enrolled 20 charts

Breast Neoplasms, Neoplasm Metastasis, Hereditary Sensory and Autonomic Neuropathies

NCT01300351 2015-04-24

Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women

249 enrolled 16 charts

Breast Neoplasms

NCT00256698 2012-08-01

FACT

514 enrolled 13 charts